Testosterone Enanthate Cost in Rhode Island 2026

What Does Testosterone Enanthate Actually Cost in Rhode Island?

Testosterone enanthate costs Rhode Island patients an average of $70 per month at retail for a standard 200 mg/mL, 10 mL vial when paying without insurance in 2026. That figure sits well below the manufacturer list price of roughly $120 per month, because generic competition among several FDA-registered manufacturers keeps retail margins thin. Prices vary by pharmacy, dose, and whether a discount card is applied.

Retail Cash-Pay Prices Across Rhode Island

Chain pharmacies in Providence, Warwick, and Cranston consistently quote $60 to $85 per month for the 10 mL multi-dose vial at 200 mg/mL. Independent pharmacies sometimes price slightly higher due to lower dispensing volume, landing closer to $80 to $100 per month without a discount program.

GoodRx and SingleCare cards can push the out-of-pocket price down to $40 to $60 per month at CVS, Walgreens, and Rite Aid locations throughout the state. These cards work at the point of sale and require no enrollment fee.

How Dose Affects Monthly Cost

Most hypogonadism protocols call for 100 to 200 mg injected intramuscularly every seven days, consistent with Endocrine Society Clinical Practice Guidelines on male hypogonadism [1]. A 10 mL vial at 200 mg/mL contains 2,000 mg total, covering 10 to 20 weeks at typical doses. Patients using 100 mg weekly spend roughly $35 per month in vial cost; those at 200 mg weekly spend close to $70 per month. Supplies (syringes, needles, alcohol swabs) add approximately $5 to $15 per month depending on source.

Testosterone enanthate is FDA-approved for male hypogonadism and delayed puberty [2]. Off-label use in transgender men and gender-diverse patients is common and supported by The Endocrine Society's transgender care guidelines, which recommend testosterone therapy to align secondary sex characteristics [3].

Rhode Island Medicaid Coverage for Testosterone Enanthate

Rhode Island Medicaid covers testosterone enanthate for male hypogonadism, but prior authorization (PA) is required. Without PA approval, the pharmacy will reject the claim. Most PA requests are resolved within 72 hours when submitted with the correct documentation.

Prior Authorization Requirements

RIte Care (the managed-care arm of Rhode Island Medicaid) typically requires:

• A confirmed diagnosis of hypogonadism (ICD-10 E29.1 for primary, or E23.0 for secondary)
• Two fasting morning total testosterone values below 300 ng/dL, drawn at least one week apart
• Documentation that the prescriber discussed risks including erythrocytosis, sleep apnea exacerbation, and infertility [1]
• The prescriber's attestation that the patient is not using testosterone for performance enhancement

The Endocrine Society guideline states: "We recommend making the diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels." [1] This language maps directly to what RIte Care auditors look for during PA review.

What Medicaid Pays After Approval

Once PA is approved, covered patients pay $0 to $3.65 per prescription depending on their RIte Care plan tier. Rhode Island's Medicaid drug fee schedule reimburses pharmacies at the Medicaid National Average Drug Acquisition Cost (NADAC) plus a dispensing fee, keeping beneficiary cost-sharing minimal.

Patients whose Medicaid coverage lapses or whose PA expires mid-treatment should request a 30-day emergency supply authorization from their prescriber immediately. Abrupt testosterone withdrawal causes fatigue, depressed mood, and loss of bone mineral density over weeks to months [4].

Compounded Testosterone Enanthate in Rhode Island: Legality and Cost

Compounded testosterone enanthate is legal in Rhode Island when prepared by a pharmacy holding a valid 503A designation under the Drug Quality and Security Act [5]. These pharmacies may compound patient-specific preparations based on a valid prescription from a licensed Rhode Island provider.

503A vs. 503B: What Rhode Island Patients Need to Know

503A pharmacies are traditional compounding pharmacies. They can prepare testosterone enanthate in custom concentrations (for example, 100 mg/mL or 250 mg/mL) for individual patients. 503B outsourcing facilities produce larger batches without patient-specific prescriptions, but they primarily supply clinics and hospitals rather than retail patients.

Rhode Island's Department of Health (RIDOH) licenses and inspects 503A pharmacies. The FDA also inspects 503A operations that compound controlled substances [5]. Testosterone enanthate is a Schedule III controlled substance under the Controlled Substances Act [6], so both DEA registration and state pharmacy licensure are required to dispense it.

Compounded Cost Compared to Branded and Generic

Compounded testosterone enanthate from a licensed Rhode Island 503A pharmacy runs approximately $80 per month for a standard concentration. That price sits between the retail generic average ($70/month) and the manufacturer list price ($120/month). The modest premium over retail generic reflects the custom concentration, smaller batch sizes, and the overhead of sterility testing.

Some patients prefer compounded versions when a specific concentration is medically necessary. For most patients, FDA-approved generic testosterone enanthate is therapeutically equivalent and less expensive [2].

Insurance Coverage for Testosterone Enanthate in Rhode Island

Most commercial insurance plans operating in Rhode Island cover generic testosterone enanthate as a Tier 1 or Tier 2 drug on formulary when hypogonadism is the documented diagnosis. BlueCross BlueShield of Rhode Island, Tufts Health Plan (now Point32Health), and UnitedHealthcare all list generic testosterone enanthate on their standard formularies for 2026, though specific tier placement can change annually.

Typical Copay Ranges by Plan Type

• Tier 1 (preferred generic): $0 to $15 per fill
• Tier 2 (non-preferred generic): $15 to $45 per fill
• High-deductible plans before deductible: patient pays full negotiated rate, typically $45 to $80 per month at in-network pharmacies

Medicare Part D covers testosterone enanthate for medically necessary hypogonadism treatment. Patients in the coverage gap pay 25% of the plan's cost for brand-name drugs; generic cost-sharing in the gap was restructured under the Inflation Reduction Act starting in 2024.

Prior Authorization on Commercial Plans

Commercial insurers in Rhode Island generally follow the same two-low-morning-testosterone-level requirement as Medicaid. BCBS of Rhode Island's 2026 prior authorization criteria specifically cite the Endocrine Society threshold of 300 ng/dL. Requests submitted with lab values, a clinical note documenting symptoms (low libido, fatigue, reduced muscle mass), and the prescriber's treatment plan are approved in 65% to 75% of cases on first submission.

Appeals succeed roughly 40% of the time when accompanied by a Letter of Medical Necessity from an endocrinologist or urologist [7]. Requesting a peer-to-peer review call between the prescriber and the insurer's medical director can increase approval odds significantly.

Telehealth Access to Testosterone Enanthate in Rhode Island

Rhode Island allows telehealth prescribing of testosterone enanthate for established patients with a documented diagnosis. The Ryan Haight Online Pharmacy Consumer Protection Act requires an in-person evaluation before any controlled substance is prescribed via telehealth unless a DEA-registered telemedicine platform qualifies under the new DEA Special Registration framework [8].

What "Established Patient" Means in Practice

For telehealth TRT in Rhode Island, most platforms require:

1. An initial lab panel: total testosterone (two fasting morning draws), LH, FSH, CBC, hematocrit, PSA (for patients over 40), and a comprehensive metabolic panel
2. A video or phone consultation with a licensed Rhode Island prescriber
3. Diagnosis confirmed by the prescriber before the first prescription is transmitted

Once the patient relationship is established, follow-up consultations and prescription refills can occur via telehealth. Follow-up labs (hematocrit every 3 to 6 months for the first year, per Endocrine Society protocol) can be ordered through any CLIA-certified lab in Rhode Island [1].

HealthRX Telehealth and Rhode Island Patients

HealthRX prescribers licensed in Rhode Island have processed testosterone enanthate prescriptions for patients in Providence, Warwick, Cranston, Pawtucket, and East Providence. Average time from completed lab upload to first prescription: 2.8 business days based on internal platform data from Q3 2024 through Q4 2024. Patients who submitted labs in the morning received same-day clinical review in 61% of cases.

The Clinical Evidence Behind Testosterone Enanthate

Understanding what the trials show helps patients and prescribers make the case to insurers and sets realistic expectations for treatment outcomes.

The Testosterone Trials (T-Trials)

The T-Trials were a coordinated set of seven placebo-controlled trials published in the New England Journal of Medicine in 2016 (N=788 men aged 65 and older with testosterone levels below 275 ng/dL) [9]. Testosterone treatment for one year significantly improved sexual function, physical function, and bone mineral density compared with placebo. The sexual function trial showed a mean improvement of 1.9 points on the Psychosexual Daily Questionnaire (PDQ) score vs. 0.3 for placebo (P<0.001).

Testosterone enanthate was not the sole formulation used in the T-Trials (a transdermal gel was the primary vehicle), but the findings are broadly applicable because testosterone bioavailability determines outcomes regardless of ester or delivery route once steady-state levels are achieved [9].

Hypogonadism Prevalence and Diagnosis Thresholds

The European Male Aging Study found that approximately 2.1% of men aged 40 to 79 met criteria for late-onset hypogonadism using the combined threshold of total testosterone below 320 ng/dL and the presence of at least three sexual symptoms [10]. In the United States, an estimated 2.4 million men have diagnosed hypogonadism [4], though underdiagnosis remains common because fatigue and low libido are attributed to aging rather than a correctable hormonal deficit.

The FDA-approved prescribing information for testosterone enanthate injection (Xyosted and generic forms) states that treatment should be initiated only when "serum testosterone levels are below normal range and there are clinical manifestations of deficiency" [2]. Prescribers who anchor their diagnosis to two separate low morning labs and documented symptoms are most likely to achieve PA approval on the first submission.

Risks Insurers and Prescribers Monitor

Testosterone therapy carries real risks that inform both clinical monitoring and insurer restrictions [1]:

• Erythrocytosis: hematocrit above 54% requires dose reduction or temporary cessation [1]
• Cardiovascular events: the TRAVERSE trial (N=5,204) found no significant increase in major adverse cardiovascular events (MACE) in men with hypogonadism on testosterone vs. Placebo over a mean 33-month follow-up [11]
• Prostate: PSA must be checked at 3 to 6 months and annually thereafter; a confirmed rise above 1.4 ng/mL in 12 months or a PSA above 4.0 ng/mL warrants urology referral [1]
• Infertility: exogenous testosterone suppresses the hypothalamic-pituitary axis, reducing sperm production; men desiring fertility should be counseled before starting therapy [3]

Discount Programs and Savings Strategies for Rhode Island Patients

Rhode Island patients who pay cash have four practical ways to reduce cost below the $70 average retail price.

Manufacturer Copay Cards

Endo Pharmaceuticals (maker of Delatestryl brand testosterone enanthate) offers a copay assistance card for commercially insured patients. Eligible patients pay $0 for the first fill. This card does not apply to Medicaid or Medicare beneficiaries under federal anti-kickback rules [12].

Pharmacy Discount Cards

GoodRx, RxSaver, and SingleCare negotiate rates with retail pharmacy networks. At CVS and Walgreens locations in Providence and Warwick, GoodRx quotes for testosterone enanthate 200 mg/mL, 10 mL vial range from $43 to $62 in early 2026. These prices update frequently; checking the card's website the day of pickup is recommended.

340B Pharmacies in Rhode Island

Rhode Island has several 340B-covered entities, including Thundermist Health Center (with locations in Woonsocket, West Warwick, and Providence) and Providence Community Health Centers. Patients who qualify as patients of these Federally Qualified Health Centers (FQHCs) may access testosterone enanthate at 340B prices, which can reduce cost below the GoodRx rate [13].

Mail-Order Pharmacies

Mail-order fills for a 90-day supply through an insurance plan's preferred pharmacy can cut per-unit cost by 20% to 30% compared with monthly retail fills, because most plans price 90-day supply at 2.5x the 30-day copay rather than 3x.

Monitoring Schedule and Ongoing Costs

Starting testosterone enanthate is not a one-time expense. The Endocrine Society recommends measuring hematocrit, testosterone levels, PSA, and bone mineral density at specific intervals [1].

First-Year Monitoring Costs in Rhode Island

• Total testosterone: measured at 3 months after initiation to confirm therapeutic range (400 to 700 ng/dL mid-injection cycle); Quest and LabCorp in Rhode Island charge $30 to $65 without insurance
• CBC with hematocrit: included in most annual wellness labs; standalone draw approximately $20 to $40
• PSA (for patients over 40): $25 to $55 standalone, often bundled in annual bloodwork
• Follow-up provider visit (in-person or telehealth): $0 to $75 depending on insurance and platform

Total first-year lab costs for a cash-pay patient typically run $150 to $300 beyond the medication itself [1]. Patients with commercial insurance covering preventive or diagnostic labs often pay $0 to $60 for the full annual monitoring panel.

Injection Supplies

Testosterone enanthate is self-injected intramuscularly, typically into the gluteus or vastus lateralis. Supplies per injection:

• 18-gauge draw needle: $0.15 to $0.25
• 23-gauge 1.5-inch inject needle: $0.15 to $0.30
• 3 mL syringe: $0.20 to $0.40
• Alcohol swabs (2 per injection): $0.05

At weekly injections, supply costs run roughly $3 to $5 per week, or $12 to $22 per month. Rhode Island pharmacies sell injection supplies over the counter without a separate prescription.

Rhode Island-Specific Regulatory Notes

Rhode Island follows federal DEA scheduling for testosterone enanthate (Schedule III) [6]. Prescriptions are valid for up to six months with a maximum of five refills. No Rhode Island state law imposes a shorter validity period for Schedule III drugs.

RIDOH does not maintain a public list of approved 503A compounding pharmacies, but the FDA's website allows patients to verify whether a compounding pharmacy has been inspected and whether any Form 483 observations have been issued [14]. Patients ordering compounded testosterone enanthate online from out-of-state pharmacies should verify that the dispensing pharmacy holds a Rhode Island non-resident pharmacy license issued by RIDOH, in addition to its home-state license and DEA registration.